BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.
Related Questions
How does this trial compare to competitor pipelines targeting Long COVID or related post‑acute infection syndromes?
What is the expected timeline for trial readout and potential FDA submission?
How many patients are being enrolled and what is the target enrollment size for the ADDRESS-LC trial?
What are the primary and secondary endpoints of the Phase 2 trial?
What is the potential market size for a therapy addressing Long COVID-related fatigue and cognitive impairment?
What regulatory pathways (e.g., Fast Track, Breakthrough Therapy) is BioVie pursuing for Beziterim?
How might the trial results impact BioVie's cash runway and need for additional financing?
What are the key risks if the trial fails to meet its endpoints?
What is the anticipated pricing and reimbursement strategy for Beziterim if approved?
How does the mechanism of action of Beziterim differentiate it from existing treatments for Long COVID neurological symptoms?